Phase 1/2Recruiting
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis
- Sponsor
- Cabaletta Bio (Industry)
- Enrolment
- 24 planned
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Interventions
- CABA-201; CABA-201
- Ages
- adults, older adults
- Registry
- NCT06359041
Full record on ClinicalTrials.gov
From the registry
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
Primary outcomes
- To evaluate incidence and severity of adverse events (AEs)
History
Primary completion expected
Last registry update
Started
Registered